The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc. (MRNA) and Merck & Co. (MRK) just posted positive Phase 3 results for a personalized mRNA cancer vaccine, and that could reignite investor interest in genomics, immunotherapy, and precision medicine ETFs.
Their therapy, given alongside Merck's Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with resected stage IIB-IV melanoma. It's the first mRNA-based cancer therapy to hit a positive Phase 3 result. Moderna's stock is surging to new heights today.
Precision Medicine Moves Into Focus
The more interesting ETF opportunity here might be broader than just mRNA. Personalized cancer vaccines work by sequencing a patient's tumor, identifying mutations that could trigger an immune response, and designing a treatment specifically for that patient. Moderna uses AI tools to help identify promising neoantigens, which ties the cancer-vaccine opportunity to the broader genomics and precision-medicine ecosystem.
That makes the iShares Genomics Immunology and Healthcare ETF (IDNA) one of the more targeted ways to play this theme. The fund holds both Moderna and Merck, giving investors exposure to companies involved in genomics, immunology, and bioengineering.
For a more aggressive genomics angle, there's the ARK Genomic Revolution ETF (ARKG). Its holdings include Twist Bioscience (TWST), 10x Genomics (TXG), Tempus AI (TEM), CRISPR Therapeutics (CRSP), and Guardant Health (GH). That gives you exposure to genetic sequencing, molecular diagnostics, and gene-editing technologies that could support personalized medicine.
Broad Biotech ETFs Already Have Exposure
If you'd rather not put all your eggs in one basket, the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB) are worth a look. XBI holds Moderna at about 2.8% of assets and uses a modified equal-weight approach across 155 biotech companies. That structure gives investors exposure to smaller biotech firms that could benefit from a wider revival in drug-development sentiment, rather than making the ETF dependent on one cancer-vaccine winner. IBB provides broader exposure to U.S. biotechnology and was up about 25% year to date.
The opportunity, however, remains early. Full clinical data, long-term survival results, regulatory filings, and the ability to manufacture personalized vaccines at scale will determine whether this breakthrough becomes a commercially significant platform.
For ETF investors, the bigger takeaway is that biotech's next growth cycle could extend beyond obesity drugs into cancer vaccines, genomics, and precision medicine.
